Rational Vaccines Announces a Clinical Trial to Determine Baseline Characteristics of Patients Diagnosed With Recurrent Symptomatic Herpes Simplex Type 2 (HSV-2) Virus
- Monday, August 15, 2022, 7:10
- Business
- Add a comment
Study to be conducted at two leading research institutions in the U.K. Results will inform protocol design of Phase 1/2 clinical trial of Company’s lead HSV-2 therapeutic vaccine candidate WOBURN, Mass. and OXFORD, England, Aug. 15, 2022 /PRNewswire/ — Rational Vaccines, a company…
About the Author
adminasapcorp has written 41834 stories on this site.